The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Indonesia Licenses Patents for Seven HIV and Hepatitis B Medicines

October 12, 2012

On September 3, Indonesia's President Dr. H. Susilo Bambang Yudhoyono signed a decree authorizing the government's use of patents for seven HIV/AIDS and hepatitis medicines. By doing so, the Indonesian government expanded access to medicines that will help save and improve the lives of people with HIV/AIDS and hepatitis B. If fully implemented, the measure will introduce widespread generic competition and generate major cost savings in the world's fourth most populous country. The decree licenses patents for several HIV medicines, and represents one of the most robust uses of pharmaceutical patent licensing power by a country since the World Trade Organization's 1995 Agreement on Trade-Related Aspects of Intellectual Property Rights.

The presidential decree greatly expands Indonesia's access to newer and more appropriate antiviral and antiretroviral treatments, including efavirenz, abacavir, didanosin, lopinavir + ritonavir, tenofovir, tenofovir + emtricitabine, and tenofovir + emtricitabine + efavirenz. For more information, including a copy of the decree (in Indonesian and an unofficial English translation), analysis, a table of the licensed medicines, and Indonesia's response to HIV and hepatitis B, visit

Back to other news for October 2012

Adapted from:
10.11.2012; Peter Maybarduk

  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
See Also
Indonesia Issues Order to Override Patents on Seven HIV, Hepatitis Drugs
Indonesia and HIV/AIDS

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: